Search research articles
Contact Us
Filters
Showing results (11-20 of 17) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 17 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 24, 2018
EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity
R-D Hofheinz, S Lorenzen, J Trojan, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 18, 2018
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'
M Haas, J T Siveke, M Schenk, et al.
BMC Cancer
|
July 27, 2022
Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer
G Sommerhäuser, A Kurreck, S Stintzing, et al.
ESMO Open
|
August 15, 2022
Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)
I Hartlapp, D Valta-Seufzer, J T Siveke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 22, 2020
Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)
M Moehler, A Maderer, P C Thuss-Patience, et al.
ESMO Open
|
February 5, 2022
Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study
S F Kruger, A Lohneis, A Abendroth, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 9, 2022
Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group
T Seufferlein, W Uhl, M Kornmann, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 17) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 17 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 24, 2018
EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity
R-D Hofheinz, S Lorenzen, J Trojan, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 18, 2018
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'
M Haas, J T Siveke, M Schenk, et al.
BMC Cancer
|
July 27, 2022
Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer
G Sommerhäuser, A Kurreck, S Stintzing, et al.
ESMO Open
|
August 15, 2022
Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)
I Hartlapp, D Valta-Seufzer, J T Siveke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 22, 2020
Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)
M Moehler, A Maderer, P C Thuss-Patience, et al.
ESMO Open
|
February 5, 2022
Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study
S F Kruger, A Lohneis, A Abendroth, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 9, 2022
Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group
T Seufferlein, W Uhl, M Kornmann, et al.
Page
of 2